Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021023876A1
Gnrh antagonists for the treatment of estrogen-dependent disorders
WO2021023877A2
Compositions and methods for the treatment of estrogen-dependent disorders
WO2020094698A2
Compositions and methods for the treatment of estrogen-dependent disorders
WO2020089190A2
Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
US2020138819A1
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US2020179390A1
Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
SG11201900461UA
Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
KR20180100120A
Alpha-amino ester and its salt form of a hydroxypropyl thiazolidinedicarboxamide derivative, crystalline polymorph
CN109790133A
The alpha-amido ester and its salt form, Crystal polymorph of hydroxypropyl thiazolidine carboxamide derivative
CN106795110A
Available crystal (3Z, 5S) 5 (methylol) 1 [(base of 2 ' 1,1 ' biphenyl of methyl 4) carbonyl] the ketone O methyloximes of pyrrolidines 3 in the method for the related illness for the treatment of OT R activity
EP2886107A1
Oral formulations of pyrrolydine derivatives
EP2845850A1
Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
